Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference

Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference




Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today the company will be participating in the upcoming 42nd Annual Canaccord Genuity Global Growth Conference in Boston, Massachusetts taking place on August 8-11, 2022, and invites investors to view the live presentation and participate in one-on-one meetings. Please see additional details below:

Canaccord Genuity Global Growth Conference

Presentation:

Thursday, August 11, 2022

Time:

8:00 to 8:25 a.m. EDT in Griffin/Robinson

Presenter:

Barry Wohl, CBO

Webcast:

https://wsw.com/webcast/canaccord76/apni/2445912

Interested parties may also access a live and archived webcast of the presentation on the “Events” section of the company website at: apnimed.com/events. One-on-one meetings will be taking place on Thursday, August 11, 2022. Investors should contact their CG representative to schedule.

About Apnimed

Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders. Learn more at apnimed.com or follow us on Twitter and LinkedIn.

About Obstructive Sleep Apnea

Obstructive Sleep Apnea (OSA) is one of the most common and serious sleep disorders and is estimated to affect more than 35 million Americans, though underdiagnosis continues to be a serious problem. OSA is characterized by partial or complete upper airway obstruction that occurs during sleep, which often leads to poor sleep, and in the long term, has been shown to exacerbate hypertension, diabetes, cardiovascular disease, and stroke. Additionally, OSA can impair work productivity, reduce functional ability, and lower quality of life.

Sleep-related muscular relaxation driven by the central nervous system is the key neurologic mechanism that causes OSA. In patients with OSA, a reduction in neuromuscular control of the upper airway during sleep leads to a corresponding relaxation of the upper airway dilator muscles. The vast majority of diagnosed patients are prescribed positive air pressure therapy devices such as continuous positive airway pressure, or CPAP, but many patients are dissatisfied with these mechanical nighttime devices and fewer than half are compliant long-term, leaving a significant population untreated, undertreated and at risk.

Contacts

Media Contact:
Courtney Heath

ScientPR

courtney@scientpr.com

Investor Contact:
Wendy Gabel

Kendall Investor Relations

wgabel@kendallir.com